Despite the competitive nature for funding in the crowded weight loss treatment space, Metsera has won $215m to advance its glucagon-like peptide-1 receptor agonist (GLP-1RA) orientated portfolio.

Metsera, however, is not a dividend stock and is, therefore, unattractive for income investors. Analysts are bullish on the biotech stock as the weight-loss drugs market is broadly expected to hit ...

Like Novo Nordisk and Lilly, Metsera has been set up to develop a pipeline of weight-loss therapies based on GLP-1 receptor agonism, with a focus on peptides and peptide-antibody conjugates.

Shares of up-and-coming weight loss drug developers Viking Therapeutics (NASDAQ:VKTX), Metsera (NASDAQ:MTSR), and Structure Therapeutics (NASDAQ:GPCR) traded sharply higher after Pfizer (NYSE ...

MET-097i achieved up to 11.3% mean placebo-adjusted weight loss at 12 weeks and exhibited a 380-hour (nearly 16-day) half-life and good tolerability. Metsera said the drug's profile is at least as ...

Shares of obesity drug developers were volatile this week amid good news for Eli Lilly's (LLY) drug candidate orforglipron, bad news for Pfizer's (PFE) danuglipron and uncertainty about whether ...

Shares of Viking Therapeutics, Altimmune, Structure Therapeutics and Metsera — all of which have weight loss drugs in clinical testing — rose in trading Monday.

Pfizer to discontinue danuglipron weight-loss drug, but has other obesity treatments ... "second-most advanced" oral GLP-1 in development. Metsera Inc. also stands to benefit, as while its oral ...